Peptic Ulcer Disease

Peptic Ulcer Disease (PUD) is a chronic gastrointestinal condition characterized by mucosal erosions in the stomach (gastric ulcers) or the first part of the small intestine (duodenal ulcers). These lesions penetrate through the muscularis mucosae layer of the GI wall. PUD primarily results from an imbalance between aggressive gastric luminal factors (acid and pepsin) and protective mucosal defense mechanisms.

• Helicobacter pylori Infection: Gram-negative bacterium causing chronic mucosal inflammation.
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Chronic use of aspirin, ibuprofen, or naproxen inhibits systemic prostaglandin synthesis.
• Physiological Stress: Severe systemic illness, burns (Curling's ulcers), or central nervous system trauma (Cushing's ulcers).
• Hypersecretory States: Zollinger-Ellison syndrome (gastrinoma).
• Lifestyle Factors: High tobacco use and heavy alcohol consumption compromise mucosal blood flow and defense.

The gastroduodenal mucosa is normally protected by a mucus-bicarbonate barrier, tight epithelial junctions, and rich mucosal blood flow regulated by endogenous prostaglandins.

• H. pylori-mediated Damage: Colonizes the antrum, producing urease, which generates toxic ammonia. The resulting inflammatory response releases cytokines, damages epithelial cells, and increases gastrin secretion, leading to hyperacidity.


• NSAID-mediated Damage: Inhibits Cyclooxygenase-1 (COX-1) enzymes, blocking the synthesis of prostaglandins ($PGE_2$ and $PGI_2$) that stimulate mucus and bicarbonate secretion and maintain mucosal blood flow.


• Acid-Pepsin Aggression: Unopposed hydrochloric acid and pepsin digest the vulnerable mucosal epithelium, causing tissue necrosis and ulceration.

• Prevalence: Affects approximately 4.1 million individuals globally annually. Lifelong prevalence is estimated at 5–10%.
• Age Distribution: Duodenal ulcers are common between ages 30 and 50; gastric ulcers typically occur in individuals over age

• Gender: Historically more common in males, but the gender ratio is now nearly equal due to increased NSAID use in women.

• Chronic NSAID, aspirin, or corticosteroid use

• Advanced age (>60 years)
• Family history of PUD
• Cigarette smoking and heavy alcohol use
• Chronic physiological stress (ICU admission)

• Mild/Uncomplicated PUD: Epigastric tenderness on deep palpation; otherwise unremarkable.
• Perforated PUD: Tachycardia, tachypnea, high-grade fever, hypoactive or absent bowel sounds, marked abdominal rigidity, guarding, and rebound tenderness.
• Bleeding PUD: Pale conjunctivae, cool/clammy skin, resting tachycardia, and hypotension.

• A. Clinical Assessment: Comprehensive history focusing on NSAID use and pain-food relationships.

• C. Imaging Studies: Upper GI series (barium swallow) or contrast-enhanced CT of the abdomen.
• D. Functional Tests: Serum gastrin levels if Zollinger-Ellison syndrome is suspected.

• F. Genetic Testing: Not routinely indicated.
• G. Differential Diagnosis: Differentiating PUD from GERD, biliary colic, pancreatitis, or gastric adenocarcinoma.

• Esophagogastroduodenoscopy (EGD): The diagnostic gold standard. It visualizes the ulcer, permits biopsy to rule out malignancy, and allows therapeutic intervention for active bleeding.
• Abdominal Computed Tomography (CT) with Contrast: Indicated for suspected complications. Typical findings in perforation include free intraperitoneal air (pneumoperitoneum) and localized duodenal/gastric wall thickening.

• Gastroesophageal Reflux Disease (GERD): Characterized by retrosternal burning (heartburn) exacerbated by recumbency, without discrete mucosal ulcerations on EGD.
• Gastric Adenocarcinoma: Presents with early satiety, weight loss, and epigastric pain. Biopsy is essential to differentiate it from benign gastric ulcers.
• Acute Pancreatitis: Severe, constant epigastric pain radiating to the back, associated with elevated serum amylase and lipase levels.

• Gastrointestinal Hemorrhage: Erosion of the ulcer into an artery (e.g., gastroduodenal artery in posterior duodenal ulcers).
• Perforation: Erosion completely through the wall, causing chemical peritonitis.
• Gastric Outlet Obstruction: Scarring or edema obstructing the pyloric channel.

• Short-term: Excellent with appropriate PPI therapy and compliance.

Screening and treating H. pylori* prior to initiating long-term NSAID or antiplatelet regimens.

• Utilizing selective COX-2 inhibitors (e.g., celecoxib) when clinically feasible in high-risk patients.

The following homeopathic remedies have been historically indicated for symptoms associated with Peptic Ulcer Disease. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Peptic Ulcer Disease.